Otulipenia: From Inflammatory Case Studies to Treatment

The team was able to successfully prescribe cytokine inhibitors to efficiently suppress the patients’ constitutive inflammation. The authors conclude their paper by suggesting that targeted cytokine therapies may be useful in diseases related to defects in the ubiquitin pathway.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

Zhou Q, Yu X, Demirkaya E, et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci USA. 2016 Sep 6;113(36):10127–10132. doi: 10.1073/pnas.1612594113. Epub 2016 Aug 24.

Two case studies demonstrate the difficulty, delay in recognizing this rare autoinflammatory disease

Progress toward targeted therapy

Systemic autoinflammatory diseases (SAIDs) are rare syndromes characterized by alterations in innate immunity that result in a variety of clinical manifestations that are usually associated with recurrent fevers.1 Thanks to advances in genetic sequencing over the past few years, monogenic causes for some of these autoinflammatory diseases, such as Yao syndrome, have been discovered.2 Previously…

Familial Mediterranean fever a frequently misdiagnosed autoinflammatory disease

Cryopyrin-Associated Periodic Syndromes: Difficult to Recognize, Diagnose, Treat

T Cells in Systemic Lupus Erythematosus

Case Report: A Long, Arduous Evaluation Capped by Genetic Testing

Nature’s Inflammation Experiment

Related Articles